These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 28652746)

  • 1. Association between serotonin transporter polymorphisms (5-HTTLPR) and the MADRS Dysphoria, Retardation, and Vegetative Subscale scores in the treatment of depression.
    Takahashi H; Higuchi H; Sato K; Kamata M; Yoshida K; Nishimura K
    Neuropsychiatr Dis Treat; 2017; 13():1463-1469. PubMed ID: 28652746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A preliminary association study between serotonin transporter (5-HTTLPR), receptor polymorphisms (5-HTR1A, 5-HTR2A) and depression symptom-clusters in a north Indian population suffering from Major Depressive Disorder (MDD).
    Basu A; Chadda RK; Sood M; Kaur H; Kukreti R
    Asian J Psychiatr; 2019 Jun; 43():184-188. PubMed ID: 31228794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A three-factor model of the MADRS in major depressive disorder.
    Suzuki A; Aoshima T; Fukasawa T; Yoshida K; Higuchi H; Shimizu T; Otani K
    Depress Anxiety; 2005; 21(2):95-7. PubMed ID: 15884092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A three-factor analytic model of the MADRS in geriatric depression.
    Parker RD; Flint EP; Bosworth HB; Pieper CF; Steffens DC
    Int J Geriatr Psychiatry; 2003 Jan; 18(1):73-7. PubMed ID: 12497559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphisms in the serotonergic system and symptom clusters of major depressive disorder.
    Kamata M; Suzuki A; Yoshida K; Takahashi H; Higuchi H; Otani K
    J Affect Disord; 2011 Dec; 135(1-3):374-6. PubMed ID: 21917318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Montgomery-Åsberg Depression Rating Scale factors in treatment-resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine.
    Borentain S; Gogate J; Williamson D; Carmody T; Trivedi M; Jamieson C; Cabrera P; Popova V; Wajs E; DiBernardo A; Daly EJ
    Int J Methods Psychiatr Res; 2022 Dec; 31(4):e1927. PubMed ID: 35749277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic Validity and Factor Analysis of Montgomery-Asberg Depression Rating Scale in Parkinson Disease Population.
    Ketharanathan T; Hanwella R; Weerasundera R; de Silva VA
    J Geriatr Psychiatry Neurol; 2016 May; 29(3):115-9. PubMed ID: 26392481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of major and minor depression in elderly persons with mild cognitive impairment--MADRS factor analysis.
    Gabryelewicz T; Styczynska M; Pfeffer A; Wasiak B; Barczak A; Luczywek E; Androsiuk W; Barcikowska M
    Int J Geriatr Psychiatry; 2004 Dec; 19(12):1168-72. PubMed ID: 15526303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A qualitative investigation of the Montgomery-Åsberg depression rating scale: discrepancies in rater perceptions and data trends in remote assessments of rapid-acting antidepressants in treatment resistant depression.
    Capodilupo G; Blattner R; Must A; Navarro SG; Opler M
    Front Psychiatry; 2024; 15():1289630. PubMed ID: 38751415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The onset of effect for escitalopram and its relevance for the clinical management of depression.
    Wade A; Friis Andersen H
    Curr Med Res Opin; 2006 Nov; 22(11):2101-10. PubMed ID: 17076970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does early improvement in depressive symptoms predict subsequent remission in patients with depression who are treated with duloxetine?
    Sueki A; Suzuki E; Takahashi H; Ishigooka J
    Neuropsychiatr Dis Treat; 2016; 12():1269-73. PubMed ID: 27307739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No predictors of antidepressant patient response to milnacipran were obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale in Japanese patients with major depressive disorders.
    Higuchi H; Sato K; Yoshida K; Takahashi H; Kamata M; Otani K; Yamaguchi N
    Psychiatry Clin Neurosci; 2008 Apr; 62(2):197-202. PubMed ID: 18412843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible Association between Serotonin Transporter Gene Polymorphism and Suicide Behavior in Major Depressive Disorder.
    Lee HY; Hong JP; Hwang JA; Lee HJ; Yoon HK; Lee BH; Kim YK
    Psychiatry Investig; 2015 Jan; 12(1):136-41. PubMed ID: 25670956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of levomilnacipran ER across symptoms of major depressive disorder: a post hoc analysis of 5 randomized, double-blind, placebo-controlled trials.
    McIntyre RS; Gommoll C; Chen C; Ruth A
    CNS Spectr; 2016 Oct; 21(5):385-392. PubMed ID: 27292817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcranial direct current stimulation (tDCS) for depression: analysis of response using a three-factor structure of the Montgomery-Åsberg depression rating scale.
    Alonzo A; Chan G; Martin D; Mitchell PB; Loo C
    J Affect Disord; 2013 Aug; 150(1):91-5. PubMed ID: 23507370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of antidepressant response to fluvoxamine obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale for major depressive disorders in Japanese patients.
    Higuchi H; Sato K; Yoshida K; Takahashi H; Kamata M; Otani K; Yamaguchi N
    Psychiatry Clin Neurosci; 2008 Jun; 62(3):301-6. PubMed ID: 18588590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotonin transporter polymorphisms and side effects in antidepressant therapy--a pilot study.
    Popp J; Leucht S; Heres S; Steimer W
    Pharmacogenomics; 2006 Mar; 7(2):159-66. PubMed ID: 16515395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies.
    Tohen M; Katagiri H; Fujikoshi S; Kanba S
    J Affect Disord; 2013 Jul; 149(1-3):196-201. PubMed ID: 23485111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential improvement in depressive symptoms for tDCS alone and combined with pharmacotherapy: an exploratory analysis from the Sertraline vs. Electrical Current Therapy for Treating Depression Clinical Study.
    Brunoni AR; Júnior RF; Kemp AH; Lotufo PA; Benseñor IM; Fregni F
    Int J Neuropsychopharmacol; 2014 Jan; 17(1):53-61. PubMed ID: 24060107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin transporter (5-HTTLPR) and norepinephrine transporter (NET) gene polymorphisms: susceptibility and treatment response of electroconvulsive therapy in treatment resistant depression.
    Kautto M; Kampman O; Mononen N; Lehtimäki T; Haraldsson S; Koivisto PA; Leinonen E
    Neurosci Lett; 2015 Mar; 590():116-20. PubMed ID: 25650523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.